Cumulative risk of exposure to IBD-directed therapy among patients with MS-IBD (red) and IBD (green) including time to initiation of (A) any immunosuppressive, (B) tumor necrosis factor inhibitors, (C) vedolizumab, or (D) thiopurines.
Sign In or Create an Account
This PDF is available to Subscribers Only
For full access to this pdf, sign in to an existing account, or purchase an annual subscription.